Lukas Hainz

Lukas Hainz

Biopharma Innovation Specialist
Lukas Hainz specializes in biopharmaceutical research and development. He unpacks research from clinical trials and explores regulatory affairs implications on the pharmaceutical industry, focusing on innovative therapies and patent development.
US Medical Tariffs Undermine Public Health
Infrastructure & Management US Medical Tariffs Undermine Public Health

The rapid proliferation of at-home medical technology has empowered millions of Americans to take control of their well-being, transforming kitchens and living rooms into the front lines of preventative care. This shift promises a future of greater health autonomy, yet this progress is now

Is AI Therapy a Cure or a Digital Prison?
Digital Health Is AI Therapy a Cure or a Digital Prison?

Facing an unprecedented global mental health crisis, where over a billion people grapple with psychological conditions, a novel and technologically sophisticated solution has rapidly gained prominence, promising immediate relief at the touch of a screen. AI-powered therapists, accessible 24/7, are

UnitedHealth Stock Falls Amid Regulatory Pressure
Patient Care UnitedHealth Stock Falls Amid Regulatory Pressure

A sudden drop in UnitedHealth Group's stock during after-hours trading has cast a harsh light on the immense regulatory and financial pressures confronting the healthcare giant, signaling that even minor policy adjustments can have significant repercussions for market sentiment. The company's

U.S. Faces Worst Measles Outbreak in 25 Years
Digital Health U.S. Faces Worst Measles Outbreak in 25 Years

A preventable disease that was declared eliminated in the United States a quarter-century ago is now surging with alarming speed, pushing the nation's public health system to its limits and raising serious questions about the state of herd immunity. With the number of infections for 2025 climbing

Why Are Radiologists Outsourcing Their Billing?
Imaging & Diagnostics Why Are Radiologists Outsourcing Their Billing?

The intricate world of medical imaging requires immense focus and precision from radiologists, but an equally complex and often more frustrating challenge is unfolding far from the diagnostic screen in the back office. As reimbursement models evolve and administrative demands intensify, radiology

Analysts Call Trump's New Drug Deals Symbolic
Regulatory & Compliance Analysts Call Trump's New Drug Deals Symbolic

Today, we're speaking with James Maitland, an expert in healthcare innovation and the intricate dynamics between the pharmaceutical industry, government policy, and financial markets. We'll be exploring the recent wave of drug pricing deals between major pharmaceutical companies and the White

Which Mental Health App Is Right for You in 2025?
Digital Health Which Mental Health App Is Right for You in 2025?

The digital landscape of mental well-being has undergone a profound transformation, evolving far beyond simple timers and relaxation sounds into sophisticated, science-backed platforms designed to provide meaningful support. These applications have matured into robust tools that leverage

Report Highlights Key Strategies to Prevent Medication Errors
Patient Care Report Highlights Key Strategies to Prevent Medication Errors

The complex environment of modern healthcare, while offering advanced treatments, also presents numerous opportunities for error, with medication administration being one of the most critical and vulnerable processes. A single misplaced vial, an ambiguous label, or a misunderstood verbal order can

Feds Charge Done Global in $100M Adderall Scheme
Digital Health Feds Charge Done Global in $100M Adderall Scheme

The rapid expansion of telehealth has been widely celebrated for its potential to democratize healthcare access, but a recent federal indictment has cast a harsh light on the industry's darker side, particularly concerning the prescription of controlled substances. Federal prosecutors have unsealed

FDA Faces Deep Divide on AI Medical Device Regulation
Regulatory & Compliance FDA Faces Deep Divide on AI Medical Device Regulation

The U.S. Food and Drug Administration (FDA) finds itself navigating a complex and fractured landscape as it endeavors to craft a regulatory framework for the real-world performance of medical devices driven by artificial intelligence (AI) and machine learning (ML). Following a call for public

Loading
Latest Articles

Subscribe to our weekly news digest.

Join now and become a part of our fast-growing community.

Invalid Email Address
Thanks for Subscribing!
We'll be sending you our best soon!
Something went wrong, please try again later